TRANSMEDICS GROUP INC (TMDX) Fundamental Analysis & Valuation

NASDAQ:TMDX • US89377M1099

130.85 USD
-3.92 (-2.91%)
At close: Mar 10, 2026
131 USD
+0.15 (+0.11%)
After Hours: 3/10/2026, 7:55:18 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TMDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Overall TMDX gets a fundamental rating of 6 out of 10. We evaluated TMDX against 184 industry peers in the Health Care Equipment & Supplies industry. While TMDX has a great health rating, its profitability is only average at the moment. TMDX is growing strongly while it is still valued neutral. This is a good combination! With these ratings, TMDX could be worth investigating further for growth investing!.


Dividend Valuation Growth Profitability Health

6

1. TMDX Profitability Analysis

1.1 Basic Checks

  • TMDX had positive earnings in the past year.
  • TMDX had a positive operating cash flow in the past year.
  • In multiple years TMDX reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: TMDX reported negative operating cash flow in multiple years.
TMDX Yearly Net Income VS EBIT VS OCF VS FCFTMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • With an excellent Return On Assets value of 17.81%, TMDX belongs to the best of the industry, outperforming 97.83% of the companies in the same industry.
  • With an excellent Return On Equity value of 40.22%, TMDX belongs to the best of the industry, outperforming 98.91% of the companies in the same industry.
  • TMDX has a Return On Invested Capital of 8.76%. This is amongst the best in the industry. TMDX outperforms 85.87% of its industry peers.
  • TMDX had an Average Return On Invested Capital over the past 3 years of 4.27%. This is below the industry average of 9.15%.
  • The last Return On Invested Capital (8.76%) for TMDX is above the 3 year average (4.27%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 17.81%
ROE 40.22%
ROIC 8.76%
ROA(3y)6.23%
ROA(5y)-5.44%
ROE(3y)12.5%
ROE(5y)-9.39%
ROIC(3y)4.27%
ROIC(5y)N/A
TMDX Yearly ROA, ROE, ROICTMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200 300 400

1.3 Margins

  • The Profit Margin of TMDX (31.43%) is better than 98.91% of its industry peers.
  • TMDX's Operating Margin of 17.93% is amongst the best of the industry. TMDX outperforms 88.59% of its industry peers.
  • Looking at the Gross Margin, with a value of 59.92%, TMDX is in the better half of the industry, outperforming 61.41% of the companies in the same industry.
  • In the last couple of years the Gross Margin of TMDX has declined.
Industry RankSector Rank
OM 17.93%
PM (TTM) 31.43%
GM 59.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.98%
GM growth 5Y-1.58%
TMDX Yearly Profit, Operating, Gross MarginsTMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. TMDX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TMDX is destroying value.
  • Compared to 1 year ago, TMDX has more shares outstanding
  • TMDX has more shares outstanding than it did 5 years ago.
  • TMDX has a better debt/assets ratio than last year.
TMDX Yearly Shares OutstandingTMDX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
TMDX Yearly Total Debt VS Total AssetsTMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • TMDX has an Altman-Z score of 5.81. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of TMDX (5.81) is better than 82.61% of its industry peers.
  • The Debt to FCF ratio of TMDX is 3.84, which is a good value as it means it would take TMDX, 3.84 years of fcf income to pay off all of its debts.
  • TMDX's Debt to FCF ratio of 3.84 is amongst the best of the industry. TMDX outperforms 80.43% of its industry peers.
  • TMDX has a Debt/Equity ratio of 1.06. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 1.06, TMDX is doing worse than 76.09% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 3.84
Altman-Z 5.81
ROIC/WACC0.92
WACC9.49%
TMDX Yearly LT Debt VS Equity VS FCFTMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 7.14 indicates that TMDX has no problem at all paying its short term obligations.
  • TMDX's Current ratio of 7.14 is amongst the best of the industry. TMDX outperforms 86.96% of its industry peers.
  • TMDX has a Quick Ratio of 6.59. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
  • TMDX has a better Quick ratio (6.59) than 88.59% of its industry peers.
Industry RankSector Rank
Current Ratio 7.14
Quick Ratio 6.59
TMDX Yearly Current Assets VS Current LiabilitesTMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. TMDX Growth Analysis

3.1 Past

  • TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 178.22%, which is quite impressive.
  • TMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.13%.
  • Measured over the past years, TMDX shows a very strong growth in Revenue. The Revenue has been growing by 88.21% on average per year.
EPS 1Y (TTM)178.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%178.95%
Revenue 1Y (TTM)37.13%
Revenue growth 3Y86.42%
Revenue growth 5Y88.21%
Sales Q2Q%32.18%

3.2 Future

  • Based on estimates for the next years, TMDX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.03% on average per year.
  • TMDX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.79% yearly.
EPS Next Y-6.95%
EPS Next 2Y15.67%
EPS Next 3Y18.54%
EPS Next 5Y12.03%
Revenue Next Year22.69%
Revenue Next 2Y20.67%
Revenue Next 3Y18.6%
Revenue Next 5Y17.79%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TMDX Yearly Revenue VS EstimatesTMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
TMDX Yearly EPS VS EstimatesTMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

4

4. TMDX Valuation Analysis

4.1 Price/Earnings Ratio

  • TMDX is valuated quite expensively with a Price/Earnings ratio of 46.57.
  • Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than 68.48% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.25, TMDX is valued quite expensively.
  • The Price/Forward Earnings ratio is 50.05, which means the current valuation is very expensive for TMDX.
  • 67.39% of the companies in the same industry are more expensive than TMDX, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.39, TMDX is valued quite expensively.
Industry RankSector Rank
PE 46.57
Fwd PE 50.05
TMDX Price Earnings VS Forward Price EarningsTMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 67.39% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, TMDX is valued a bit cheaper than the industry average as 76.63% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 33.6
EV/EBITDA 34.22
TMDX Per share dataTMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The decent profitability rating of TMDX may justify a higher PE ratio.
  • A more expensive valuation may be justified as TMDX's earnings are expected to grow with 18.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.67%
EPS Next 3Y18.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TMDX Dividend Analysis

5.1 Amount

  • No dividends for TMDX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TMDX Fundamentals: All Metrics, Ratios and Statistics

TRANSMEDICS GROUP INC

NASDAQ:TMDX (3/10/2026, 7:55:18 PM)

After market: 131 +0.15 (+0.11%)

130.85

-3.92 (-2.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-06
Inst Owners111.11%
Inst Owner Change-1.75%
Ins Owners2.99%
Ins Owner Change1.41%
Market Cap4.49B
Revenue(TTM)605.49M
Net Income(TTM)190.29M
Analysts83
Price Target148.92 (13.81%)
Short Float %24.77%
Short Ratio10.77
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.66%
Min EPS beat(2)32.92%
Max EPS beat(2)84.39%
EPS beat(4)4
Avg EPS beat(4)96.18%
Min EPS beat(4)32.92%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)170.32%
EPS beat(12)10
Avg EPS beat(12)118.73%
EPS beat(16)13
Avg EPS beat(16)92.69%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)1.22%
Revenue beat(4)3
Avg Revenue beat(4)4.11%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)5.48%
Revenue beat(12)10
Avg Revenue beat(12)10.09%
Revenue beat(16)14
Avg Revenue beat(16)16.58%
PT rev (1m)0%
PT rev (3m)1.1%
EPS NQ rev (1m)-6.58%
EPS NQ rev (3m)-5.48%
EPS NY rev (1m)-11.51%
EPS NY rev (3m)-10.81%
Revenue NQ rev (1m)1.51%
Revenue NQ rev (3m)1.51%
Revenue NY rev (1m)1.77%
Revenue NY rev (3m)1.79%
Valuation
Industry RankSector Rank
PE 46.57
Fwd PE 50.05
P/S 7.41
P/FCF 33.6
P/OCF 23.27
P/B 9.49
P/tB 9.77
EV/EBITDA 34.22
EPS(TTM)2.81
EY2.15%
EPS(NY)2.61
Fwd EY2%
FCF(TTM)3.89
FCFY2.98%
OCF(TTM)5.62
OCFY4.3%
SpS17.65
BVpS13.79
TBVpS13.4
PEG (NY)N/A
PEG (5Y)N/A
Graham Number29.53
Profitability
Industry RankSector Rank
ROA 17.81%
ROE 40.22%
ROCE 11.09%
ROIC 8.76%
ROICexc 17.48%
ROICexgc 17.98%
OM 17.93%
PM (TTM) 31.43%
GM 59.92%
FCFM 22.06%
ROA(3y)6.23%
ROA(5y)-5.44%
ROE(3y)12.5%
ROE(5y)-9.39%
ROIC(3y)4.27%
ROIC(5y)N/A
ROICexc(3y)8.3%
ROICexc(5y)N/A
ROICexgc(3y)8.55%
ROICexgc(5y)N/A
ROCE(3y)5.4%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.98%
GM growth 5Y-1.58%
F-Score7
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 3.84
Debt/EBITDA 3.7
Cap/Depr 217.96%
Cap/Sales 9.79%
Interest Coverage 10.15
Cash Conversion 142.04%
Profit Quality 70.2%
Current Ratio 7.14
Quick Ratio 6.59
Altman-Z 5.81
F-Score7
WACC9.49%
ROIC/WACC0.92
Cap/Depr(3y)910.54%
Cap/Depr(5y)653.45%
Cap/Sales(3y)34%
Cap/Sales(5y)25.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)178.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%178.95%
EPS Next Y-6.95%
EPS Next 2Y15.67%
EPS Next 3Y18.54%
EPS Next 5Y12.03%
Revenue 1Y (TTM)37.13%
Revenue growth 3Y86.42%
Revenue growth 5Y88.21%
Sales Q2Q%32.18%
Revenue Next Year22.69%
Revenue Next 2Y20.67%
Revenue Next 3Y18.6%
Revenue Next 5Y17.79%
EBIT growth 1Y189.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.48%
EBIT Next 3Y45.75%
EBIT Next 5Y46.88%
FCF growth 1Y265.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y295.14%
OCF growth 3YN/A
OCF growth 5YN/A

TRANSMEDICS GROUP INC / TMDX FAQ

Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?

ChartMill assigns a fundamental rating of 6 / 10 to TMDX.


Can you provide the valuation status for TRANSMEDICS GROUP INC?

ChartMill assigns a valuation rating of 4 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.


How profitable is TRANSMEDICS GROUP INC (TMDX) stock?

TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 6 / 10.


How financially healthy is TRANSMEDICS GROUP INC?

The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 7 / 10.